![]() That standard has not changed in over a decade. “The current standard of care for inoperable biliary tract cancer is combined chemotherapy. There have been few treatment advances in this area, which makes the results of TOPAZ-1 encouraging, according to experts in the field. “TOPAZ-1 is the first phase 3 trial to show that adding immunotherapy to standard chemotherapy can increase survival in biliary tract cancer, and importantly, does so without inducing any new serious side effects,” said principal investigator Do-Youn Oh, MD, PhD, professor in the Division of Medical Oncology, Department of Internal Medicine at Seoul National University Hospital and Seoul National University College of Medicine, said in a statement.īiliary tract cancers are relatively rare, and diagnosis often occurs when the disease has already advanced, which often makes for a grim prognosis. Meanwhile, gemcitabine promotes the death of cancer cells that are rapidly dividing, while cisplatin blocks the DNA repair mechanisms in cancer cells, leading to their death. The immune checkpoint inhibitor durvalumab blocks the PD-L1 protein on the surface of immune cells, which lets the immune system to recognize and attack cancer cells. The 3 therapies work in concert to attack cancer cells and promote their demise. At 24 months, the difference was 24.9% and 10.4%. Pairing durvalumab (Imfinzi) with the chemotherapy combination gemcitabine and cisplatin improved overall survival (OS) by 20% in patients with advanced biliary tract cancer, compared with the current standard of giving the chemotherapy combination alone, according to phase 3 trial results released today.įindings from TOPAZ-1 will be presented at the American Society of Clinical Oncology Gastrointestinal Cancers Symposium (ASCO GI), set for January 20-22 in San Francisco, California.ĭata show that after 18 months on the study, 35.1% of those taking durvalumab with the chemotherapy combination were still alive, compared with 25.6% taking just the chemotherapy.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |